Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Nanomedicine (Lond). 2012 Jun 18;7(10):1507–1519. doi: 10.2217/nnm.12.27

Figure 2. In vitro serial effect of Sn-2 lipase-labile fumagillin prodrug-incorporated nanoparticles on HUVEC cell metabolic activity (A) and proliferation (B).

Figure 2

The αvβ3-targeted Sn-2 phospholipase-labile PD nanoparticles had equivalent effectiveness in vitro on HUVEC (A) cell metabolic activity and (B) proliferation, compared with the αvβ3-targeted native fumagillin nanoparticles used in several previous studies [1–6]. Collectively, these data affirm the in vitro sensitivity of proliferating endothelial cells to the effects of αvβ3-targeted fumagillin nanoparticles, included in the native or PD form.

*p < 0.05 (indicates significant difference).

HUVEC: Human umbilical vein endothelial cell; NT: Nontargeted; PD: Prodrug.